A Phase 2, Open-Label, 2-Cohort,
Multicenter Study of INCB050465, a PI3Kä Inhibitor, in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a BTK Inhibitor, NCT03235544
PURPOSE OF THIS CLINICAL RESEARCH TRIAL
This is a Phase 2, open-label, 2-cohort study designed to evaluate the efficacy and safety of 2 INCB050465 treatment regimens in subjects with relapsed or refractory mantle cell lymphoma (MCL) previously treated either with or without a Bruton’s tyrosine kinase (BTK) inhibitor.
MORE DETAILS ON THIS LYMPHOMA TRIAL
17093 / (CITADEL-205)- INCB050465-205 / NCT03235544 / Call PM 7-20-2018
TRIAL AVAILABLE AT THESE LOCATIONS
All RMCC Locations